Help appealing denials for this mitochondrial therapy for Barth syndrome.

Appeal Your Forzinity Denial

Get access to this breakthrough treatment for Barth syndrome cardiomyopathy.

Understanding Your Forzinity (elamipretide) Denial

Forzinity (elamipretide) is a mitochondrial-targeted peptide approved for improving muscle strength in patients with Barth syndrome weighing at least 30 kg. Barth syndrome is an ultra-rare genetic disorder causing cardiomyopathy and muscle weakness. Insurance denials are common for rare disease medications, but this is an essential treatment.

Common Reasons for Denial

! Prior authorization required
! Barth syndrome diagnosis not genetically confirmed
! Weight requirement not documented
! Ultra-high cost orphan drug
! Rare disease with limited coverage policies
! New drug with limited experience

How We Help

We help you document your Barth syndrome diagnosis, genetic testing results, cardiac function, muscle weakness, and how this condition impacts your daily life.

Start your Forzinity appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Elamipretide targets the inner mitochondrial membrane, improving mitochondrial function in Barth syndrome.

✓ Clinical trials demonstrated improvement in muscle strength and functional capacity.

✓ Barth syndrome affects approximately 1 in 300,000-400,000 births, making it an ultra-rare disease.

✓ No other approved therapies specifically target the underlying mitochondrial dysfunction in Barth syndrome.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

Stealth BioTherapeutics Patient Support

Patient support program for Forzinity offering access assistance and financial support for eligible patients.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

National Organization for Rare Disorders (NORD)

Leading patient advocacy organization for rare disease community.

Global Genes

Leading rare disease patient advocacy organization connecting and empowering patients.

Frequently Asked Questions

Barth syndrome is a rare X-linked genetic disorder caused by TAZ gene mutations. It affects the heart (cardiomyopathy), skeletal muscles, immune system, and growth, primarily in males.

Include genetic testing confirming TAZ mutation, documentation of current weight (must be at least 30 kg), cardiac function tests showing cardiomyopathy, and muscle strength assessments.

Ready to Fight Your Forzinity (elamipretide) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Stealth BioTherapeutics. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.